作为骨髓瘤治疗点的KIAA1429:挑战线性铁亡途径并评估转化障碍
DuJiang Yang1,2, Lin Yu1, Zhijun Ye1
1The Affiliated Traditional ChineseMedicine Hospital Southwest Medical University, NO.182, Chunhui Road, Longmatan District, Luzhou, Sichuan Province, 646000, People's Republic of China.
概括
这项研究质疑KIAA1429沉默是否仅通过Nrf2/NQO1通路促进骨肉瘤中的铁亡. 它强调了对KIAA1429更细致的观点的需要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- KIAA1429 是一种m6A编辑器,与骨髓瘤进展有关.
- 谢和其他人. 拟议的KIAA1429沉默通过Nrf2/NQO1轴促进铁亡.
- 这种拟议的机制可能过于简单化.
研究的目的:
- 批判性地评估将KIAA1429,铁死和骨肉瘤联系在一起的拟议机制.
- 评估Nrf2/NQO1通路在KIAA1429的影响中的直接性和独占性.
- 评估向KIAA1429在骨髓瘤中的转化潜力.
主要方法:
- 文献审查和对现有数据的批判性分析.
- 检查KIAA1429作为全球RNA修饰剂的已知功能.
- 评估潜在的非目标效应和抵抗机制.
主要成果:
- Nrf2不可或缺的直接作用并没有被遗传救援最终确立.
- 忽略了KIAA1429对其他铁灭调节剂 (GPX4,SLC7A11) 的类作用.
- 在正常细胞和抵抗机制中的点毒性没有被评估.
结论:
- 提出的Nrf2/NQO1轴作为唯一的机制是有问题的.
- 向KIAA1429用于骨髓瘤治疗面临着重大的药理学挑战.
- 需要对KIAA1429在骨髓瘤中的作用进行更细致的解释.
更多相关视频
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
11.1K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.7K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K